These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 18528294)
1. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. Redman BG; Chang AE; Whitfield J; Esper P; Jiang G; Braun T; Roessler B; Mulé JJ J Immunother; 2008; 31(6):591-8. PubMed ID: 18528294 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914 [TBL] [Abstract][Full Text] [Related]
3. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Chang AE; Redman BG; Whitfield JR; Nickoloff BJ; Braun TM; Lee PP; Geiger JD; Mulé JJ Clin Cancer Res; 2002 Apr; 8(4):1021-32. PubMed ID: 11948109 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169 [TBL] [Abstract][Full Text] [Related]
6. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Geiger JD; Hutchinson RJ; Hohenkirk LF; McKenna EA; Yanik GA; Levine JE; Chang AE; Braun TM; Mulé JJ Cancer Res; 2001 Dec; 61(23):8513-9. PubMed ID: 11731436 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. Chang JW; Hsieh JJ; Shen YC; Ho E; Chuang CK; Chen YR; Liao SK; Chen JS; Leong SP; Hou MM; Chang NJ; Wang CH Melanoma Res; 2009 Oct; 19(5):309-15. PubMed ID: 19750589 [TBL] [Abstract][Full Text] [Related]
8. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607 [TBL] [Abstract][Full Text] [Related]
9. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874 [TBL] [Abstract][Full Text] [Related]
10. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial). Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. de Rosa F; Ridolfi L; Ridolfi R; Gentili G; Valmorri L; Nanni O; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Riccobon A; Parisi E; Romeo A; Turci L; Guidoboni M J Transl Med; 2014 Jul; 12():209. PubMed ID: 25053129 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734 [TBL] [Abstract][Full Text] [Related]
13. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Scarpi E; Guidoboni M; Migliori G; Sanna S; Tauceri F; Verdecchia GM; Riccobon A; Valmorri L; Ridolfi R Clin Dev Immunol; 2010; 2010():504979. PubMed ID: 20936106 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. Santin AD; Bellone S; Palmieri M; Zanolini A; Ravaggi A; Siegel ER; Roman JJ; Pecorelli S; Cannon MJ J Virol; 2008 Feb; 82(4):1968-79. PubMed ID: 18057249 [TBL] [Abstract][Full Text] [Related]
16. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Märten A; Flieger D; Renoth S; Weineck S; Albers P; Compes M; Schöttker B; Ziske C; Engelhart S; Hanfland P; Krizek L; Faber C; von Ruecker A; Müller S; Sauerbruch T; Schmidt-Wolf IG Cancer Immunol Immunother; 2002 Dec; 51(11-12):637-44. PubMed ID: 12439609 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259 [TBL] [Abstract][Full Text] [Related]
19. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085 [TBL] [Abstract][Full Text] [Related]
20. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]